SINUS-52

Patients experienced improvement in QoL, as measured by SNOT-22, as follows:

• Week 4 in SINUS-52. LSM difference between DUPIXENT 300 mg Q2W + INCS (n=150) and placebo + INCS (n=153): -10.57 (95% CI: -14.47, -6.66) (-18.97 from a baseline score of 50.16 vs -8.40 from a baseline score of 53.48, respectively)⁴
• Week 24 in SINUS-52. LSM difference between DUPIXENT 300 mg Q2W + INCS (n=150) and placebo + INCS (n=153): -16.76 (95% CI: -20.85, -12.67) (-27.08 from a baseline score of 50.16 vs -10.32 from a baseline score of 53.48, respectively)⁴

Analysis was not multiplicity controlled. Results are descriptive. Definitive conclusions cannot be made.⁴

• Week 52 in SINUS-52. LSM difference between DUPIXENT 300 mg Q2W + INCS (n=150) and placebo + INCS (n=153): -20.96 (95% CI: -25.03, -16.89) (-29.84 from a baseline score of 50.16 vs -8.88 from a baseline score of 53.48, respectively)⁴

• Week 24 in SINUS-52 (key secondary endpoint). LSM difference between DUPIXENT 300 mg Q2W + INCS (n=295, pooled arms) and placebo + INCS (n=153): -17.36 (95% CI: -20.87, -13.85) (-27.77 from a baseline score of 51.02 vs -10.40 from a baseline score of 53.48, respectively) (P<0.0001)⁴

The SNOT-22 score is calculated from a patient questionnaire in which 22 symptoms are rated from 0 (“no problem”) to 5 (“problem as bad as it can be”) based on the severity and frequency of each particular item.^1,9

22-item Sino-Nasal Outcome Test (SNOT-22) score (range 0-110): reduced score indicates improvement.¹

INCS, intranasal corticosteroid; LSM, least squares mean; Q2W, once every 2 weeks.

See more about how DUPIXENT can improve symptoms and QoL